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ABSTRACT
Autocrine Growth Regulation of a Cloned
Murine T Helper Cell Line
Jay Bruce Horowitz
Yale University School of Medicine
1987
The growth and proliferation of mammalian cells are controlled in part by
polypeptide hormones found in the serum.

Malignant or transformed cells

appear to require no or lower concentrations of growth-controlling factor(s) as
compared with normal or untransformed cells.

It has therefore been suggested

that cells could become malignant via the aberrant production of polypeptide
growth-controlling factor(s) acting in an autocrine manner through functional
cell membrane receptors resulting in uncontrolled proliferation.

Recently, the

“autocrine hypothesis” has been further defined in that malignant transformation
may be the result not only from excessive production, expression, and action of
positive autocrine growth factors but also the failure of cells to synthesize,
express or respond to specific negative growth factors that they normally
release to control their own growth.
It had been shown that the T helper cell line DIO secretes large amounts
of a T cell growth factor, believed to be 1L-2, upon crosslinking of its antigenclass II MHC products receptor yet failed to proliferate.

However, if the

monokine IL-1 was present during stimulation potent proliferation occurred.
Furthermore, DIO cells have to been shown to both respond to IL-2 derived
from a T cel! hybridoma and to express functional IL-2 receptors.

Thus in the

presence of both functional T cell growth factor and IL-2 receptors this clone
fails to proliferate.

It appears that there are at least two possible explanations of why DIO
fails to proliferate in response to crosslinking of its antigen-class II MHC
products receptor. The first explanation is that DIO does not secrete IL-2 but IL4.

DIO cells do not respond vigorously to purified IL-4, probably because the

cells do not express significant numbers of IL-4 receptors. However, if IL-1 and
IL-4 are incubated together with DIO cells, the cells are able to proliferate in
response to IL-4.

Secondly, in addition to IL-4, DIO produces an inhibitor of T

cell responses to IL-2 and possibly IL-4. Although the relative contribution each
plays has yet to be definitively determined, the initial evidence suggests that the
IL-1 dependence of DIO's autocrine growth is largely if not entirely due to the
requirement for IL-1 as a cofactor for IL-4 driven T cell growth.
mechanisms of this IL-1 dependence is currently being studied.

The precise
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Introduction
Historical Perspective
Although many of the advances in immunology have occurred in the past
twenty years, references to the immune system and immunology can be found
dating back to the bible and before. Thucydides, in his description of the plague
that struck Athens in 430 b. c. noted: “Yet it was with those who had recovered
from the disease that the sick and the dying found most compassion.

These

knew what it was from experience, and had now no fear for themselves; for the
same man was never attacked twice-never at least fatally.”1

In describing the

plague of the Byzantine emperor Justinian a thousand years later, Procopius
said “at a later time it [the plague] came back; then those who dwelt round about
this land, whom formerly it had afflicted most sorely, it did not touch at all.”1

In

time this resistance to reinfection become known as immunity, from the Latin

immunitas 2
It was not until the late 19th century when the importance of cells was
finally appreciated that immunology became a true science.

Before that time,

medicine had been under the domination of the old Greek view that disease
was based on imbalances in the “essential bodily humors.” Metchnikoff, based
on his observations of phagocytic cells in marine invertebrates, suggested that
vertebrate phagocytic cells performed a similar protective function3.

Shortly

after the initial description of the phagocytic theory, it came under severe and
protracted attack with the fiercest criticism coming from Baumgarten3. At about
the same time, Nuttall noted that the serum of normal animals contained
substances which were toxic to certain microorganisms, eg. bacteria, and
whose properties were enhanced when the host was immunized1. In 1890 von
Behring and Kitasato described humoral immunity to diphtheria and tetanus1With this and other published reports, the humoral theory of immunology gained

2
converts while supporters of the cellular theory dwindled.

It was not until

Medawar's observations on tissue transplantation and immunologic tolerance,
Burnet's emphasis on the importance of cells in antibody production, and
descriptions on the role of the thymus in immunologic deficiency states in the
1950s and 1960s that a renewed interest cellular immunology finally occurred1.
Brief Overview

The immune system has classically been divided into cell mediated and
humoral components.

Humoral immunity is provided by antibodies that

circulate in the serum and in the lymphatic fluid. Cellular immunity, as its name
implies, is provided by specific cells in the immune system.

Although there is

much overlap between the two “arms,” for descriptive purposes it is still relevant
to talk in these terms.

People with deficiencies in humoral immunity are

plagued with recurrent or chronic sinopulmonary infections, meningitis, and
bacteremias caused by pyogenic bacteria while abnormalities in cell mediated
immunity predisposes individuals to disseminated viral and fungal as well as
protozoal infections4.
The

constituents

of

the

immune

system

include

lymphocytes,

macrophages and their related cells, eg. dendritic cells of the spleen, Kupffer
cells of the liver, epithelial Langerhans cells, etc., and specialized epithelial
cells, such as those found in the thymus5.

These cells may be found in

organized tissues and organs, such as the lymph nodes, the spleen, the tonsils,
the Peyer's patches of the intestine, the thymus, and the bone marrow or may
circulate throughout the body in the blood and in the lymphatic fluid5.
There are two major classes of lymphocytes: B lymphocytes which are
the precursors of antibody secreting plasma cells and T lymphocytes which are
thymus dependent and mediate important regulatory functions including
augmentation

and suppression

of the immune

response

and

antibody
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production5.

Both B lymphocytes and T lymphocytes are derived from

hematopoietic stem cells located within the bone marrow and in other
hematopoietic tissue.

Mononuclear phagocytes are the third type of cell that is

intimately involved in the development and expression of humoral and cellmediated

immunity6.

These cells participate in a number of events in the

immune response including host defense against microorganisms, cellular
interactions with lymphocytes, and secretion of monokines6.

ANTIGEN PRESENTING CELLS
The first step that occurs when a foreign material (antigen) enters the
body

is

its

uptake

by

cells

of

the

phagocytic

system,

usually

by

nonimmunological means6. Antigen is then processed by the cell such that an
antigen fragment7 or native antigen8 is present on the surface of the antigen
presenting cell (APC).

Antigen in association with self class

II

major

histocompatibility complex (MHC) products is then presented to the T cell
receptor complex9.

This in turn, leads to T cell activation, proliferation10 and

production of various T cell lymphokines, primarily T cell growth factor
(TCGF)11.
Currently, there is much controversy over which cell type or types present
antigen

in vivo.

A number of different cell types have been reported in the

literature: peritoneal and splenic macrophages12, splenic dendritic cells13,
epidermal Langerhan cells14, Kupffer cells15, alveolar macrophages16, B
cells17, and B cell tumors18.

Each, under the appropriate experimental

conditions, are able to act as APCs.

The biological significance of all these

different cell types acting as APCs remains unknown.

4

T Lymphocytes
Overview

T lymphocytes (or T cells), so called because their maturation requires
processing in the thymus19, are the central cells in the cellular immune
response. They generate cytotoxic responses to alloantigens, exert helper and
suppressor effects on the production of antibodies, and initiate graft versus host
responses20.

Cantor and Boyse, in a series of elegant experiments,

demonstrated that commitment of T cells to participate exclusively in either
helper or cytotoxic function is a differentiative process that takes place before
they encounter antigen20.

They further showed that T cells involved in helper

responses expressed different surface antigens (Ly-1+2_) than those involved in
killing allogeneic target cells (Ly-1‘2+)20. Cantor and Boyse also noted that Ly1+2‘T cells recognized self class II MHC products while Ly-I'2+T cells
recognized self class I MHC products21.

Rao et al. confirmed the initial

observation of Cantor and Boyse by using 21 T cell clones derived from mixed
lymphocyte cultures and studying the association of Ly phenotype with function
and specificity for MHC products22.
As mentioned above, antigen together with class II MHC products are
presented by APCs to T helper cells.

This in turn results in proliferation and

elaboration of a variety of lymphokines. The T helper cell binds the antigen-self
class II MHC complex through its receptor, a hetrodimer composed of a disulfide
linked acidic (a) and basic ((3) chains23. Although the antigen-self class II MHC
complex is the apparent ligand for the T cell receptor, it appears that receptor
cross linking or aggregation is the necessary requirement for T cell activation24.
In addition to receptor cross linking it has been shown that certain T cells
require interleukin 1 (IL-1) for the secretion of T cell lymphokines, mainly

.
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interleukin 2 (IL-2)25-26; while, in other T cells IL-1 was required for the
expression of IL-2 receptors27. However Malek et al., using a heterogeneous
population of resting T helper cells essentially depleted of accessory cells,
found that IL-1 neither induced IL-2 secretion nor promoted IL-2 receptor
expression28.
Activation
In addition to activation via antigen and self class II MHC products, T
helper cells may be activated with plant lectins such as phytohemagglutinin
(PHA) and concanavalin A (Con A)29, calcium ionophores such as A2318730,
and monoclonal antibodies31-32,33,34
The term lectin refers to a large collection of carbohydrate binding
multimeric glycoproteins derived from plant and animal sources35. There are at
least several hundred plant extracts that interact with and agglutinate
erythrocytes; however, only a small number bind to lymphocytes and induce a
mitogenic response36. Of these PHA from the red kidney bean (Phaseola
vulgaris) and Con A from the jack bean (Canavalia ensiformis) are the most
widely used T cell lectins36. Although the mechanism by which lectins interact
with cell surface proteins remains largely unknown, they apparently work by
cross-linking cell surface molecules29.

In a recent study, Tsien et al. have

partially unraveled the mechanism of lectin induced activation with their finding
of increased intracellular calcium following lectin binding37.
Calcium ionophores, such as A23187, work by directly inserting into the
plasma membrane forming a calcium ion channel which results in a rapid influx
of calcium38. Akerman and Andersson, using purified human T cells, showed
polyclonal proliferation following treatment with A2318730.

This finding

combined with those of Tsien et al. suggest that an increase in cytosolic calcium
directly triggers the proliferative response.

.
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Monoclonal antibodies directed at the T cell receptor complex have
allowed further definition of the mechanism involved in activation of T cells31'34.
Kaye et al. described a monoclonal antibody (3D3) specific for the cloned
helper T cell line D10.G4.1 (DIO) that completely replaced the requirement for
antigen and self class II MHC products in the activation of that clone24'34.
Using the Fab fragment from that monoclonal antibody as an inhibitor of
activation, activation of DIO by either antigen-self class II MHC products or
allogeneic class II MHC products was blocked. The ability of the Fab fragment
to induce proliferation was restored when anti-mouse immunoglobulin was
used to cross link the Fab fragments. They also noted that the ability of 3D3 to
activate DIO was dependent on a signal from an accessory cell and that by
using either IL-1 or IL-2 the requirement for accessory cells could eliminated.
(Note: The source of IL-2 used in those experiments has recently been shown to
contain an additional TCGF, see results).

The conclusions to be drawn from

these experiments are (1) the T cell receptor complex is the binding site for both
antigen-self class II MHC products and allogeneic-class II MHC products, (2)
receptor cross linking and not receptor occupancy provides the necessary
signal for activation , and (3) activation for T cell growth is a two signal process.
Classification of T Helper Cells

Murine T helper cells appear to be fairly uniform when viewed in the
context of surface markers such as Ly-1; however, when assessed by functional
criteria at least two39’40’41’42 and as many as four43 different types of T helper
cells have been described.

Mosmann et al. screening a large panel of antigen-

specific murine T helper cell clones found that two types of functionally distinct
cells could be distinguished based on lymphokine secretion44.

Mosmann Type

1 T helper cells when stimulated with antigen and APCs or Con A produced IL2, interferon-y (IFN-y), granulocyte-macrophage colony stimulating factor (GM-

.
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CSF), and interleukin 3 (IL-3) while Mosmann Type 2 cells secreted IL-3 and
interleukin 4 (IL-4).
functionally

distinct

Kim et al.; however, divided Lyl+2‘ cells into four
types

phosphorylcholine-specific

based
(PC)

upon

their

plaque-forming

ability
cell

to

induce

response,

a

their

requirement for the presence of antigen during induction of B cell responses,
and their activation of T15-bearing or non-TI 5-bearing B cells43.
prototypic idiotypic determinant characteristic of the

(T15 is the

BALB/c PC-binding

myeloma protein TEPC-15)45. Types 1 and 2 induce B cells to secrete anti-PC
antibodies in an antigen specific class ll-MHC products restricted fashion. Type
3 cells induce antigen-specific class

ll-MHC products

restricted

B cell

proliferation, but do not lead to specific antibody formation, and Type 4 cells are
autoreactive and induce antigen-independent B cell activation and antibody
secretion.

Killar et al. have recently confirmed the finding that IL-4 producing T

cell lines do not secrete IL-2, IFN-y, and lymphotoxin46.

They have further

shown that activation of antigen-specific B cells by T helper cells appears to
require IL-4, and those that do not produce IL-4 fail to induce antigen-specific B
cell responses.

Lymphokines
Overview

Lymphokines are

non-antigen-specific,

produced by cells of the immune system47.

hormone-like

polypeptides

They include interleukins,

interferons, hematopoietic colony-stimulating factors, macrophage-modulating
factors, and chemotactic factors48.

Although they perform many diverse

functions, most can be grouped into one of four categories: growth factors,
activation

and/or differentiation

factors,

lymphotoxins,

and chemotactic

factors47.

These categories are by no means mutually exclusive in that it is
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possible for a lymphokine to have more than one function; for example, IL-4
both activates resting B cells49 and promotes the growth of certain T helper cell
lines50.

Like the hormones of the endocrine system, lymphokines are active in

concentrations ranging from 10‘10 to 10'12m48 and have receptors that are
highly specific; for example, the high affinity IL-2 receptor has a dissociation
constant of 5-20 x 10'12 M51. Given all of this, it is not surprising that the study
of lymphokines is one the leading fields of research in cellular and molecular
immunology.
Interleukin 1 (IL-1)

In the late 1940s it was first suggested that fever was initiated by a
soluble factor produced and released by activated macrophages52.

A protein

with similar pyrogenic properties appropriately named endogenous pyrogen
(EP) was demonstrated in the plasma of rabbits made febrile by injection of
bacteria53.

In the early 1970s Gery et al. reported that macrophages released

one or more mitogenic substances which they called lymphocyte activating
factor (LAF) that greatly potentiated the response of T lymphocytes to mitogens
such as PHA but did not stimulate B cells in the absence of T cells54’55’56.
Initial characterization of both EP and LAF revealed that agents which
stimulated production of EP also stimulated LAF release, EP and LAF had
similar kinetics for release, and that the two had nearly identical molecular
weights

and

isoelectric

points53.

In the late 1970s and early 1980s

Rosenwasser et al. reported that highly purified leukocytic pyrogen (also known
as EP) replaced the soluble products of murine peritoneal exudate cells in the T
cell proliferative response to antigen57 and enhanced the murine thymocyte
proliferation response to PHA58 and thus established that EP and LAF were
indeed the same molecule.

.
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Interleukin 1 was first purified by Blyden and Handschumacher who
found that human LAP had an apparent molecular weight of approximately
13,000 daltons59.

Subsequent studies based on IL-1 obtained from human,

mouse, and mouse macrophage cell lines have revealed a molecular weight of
between 12,000 and 16,000 daltons60. Mizel and Mizel using culture fluid from
the macrophage cell line P388D.1
homogeneity60.

first purified murine IL-1

to apparent

They noted a molecular weight of 14,000 daltons, three

charged species which they termed a, (3, y, and a biological activity range within
10"11 to 10’10 M. The complementary DNAs (cDNA) for both murine and human
IL-1 have recently been cloned, expressed, and sequenced61 -62.

The murine

IL-1 cDNA codes for a polypeptide precursor of 270 amino acids61 with the
biologically active polypeptides at least 127 amino acids long and derived from
the carboxyl terminus of the 270 amino acid precursor63.

Two distinct but

distantly related cDNAs (IL-1 a and IL-1 (3) encoding for human IL-1 have been
described62.

Dower et al. have shown the IL-1 binds to a plasma membrane

receptor with an apparent affinity of approximately 0.2-2 xIO'10 M and molecular
weight of about 80,000 daltons64-65.

Bird and Saklatvala66 , Dower et al. 67,

and Kilian et al.68 have all independently shown that the IL-1

receptor on

fibroblasts and on T cells binds both IL-1 a and IL-1 (3.
In addition to its role as a mediator of the acute-phase response, IL-1 acts
on a number of cells in the immune system including B cells and T cells69.
Lipsky et al. using antiserum against human leukocytic pyrogen showed that IL1

plays a necessary role in B cell proliferation and in the generation of

immunoglobulin-secreting cells70.

Howard et al. noted that IL-1 and IL-4 acted

synergistically in the proliferation of anti-IgM activated B cells71.

Gillis and

Mizel observed that for certain T cell tumor lines IL-1 was necessary for the
production of IL-226.

Kaye et al. using the cloned helper T cell line D10 found
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that IL-1 induced IL-2 receptor expression27.

These findings implicate 11-1 as

one of the key mediators of the immune response.
INTERLEUKIN 2 (IL-2)

Interleukin 2, originally termed TCGF,was first produced by stimulating
normal human peripheral blood lymphocytes with PHA72.

Shortly after the

initial description of TCGF, several investigators reported the long term growth
of normal human T cells73 and tumor-specific cytotoxic T cells74 using media
supplemented with this factor.

Using the tumor-specific cytotoxic T cell line

(CTLL) Gillis et al. were able to develop a sensitive microassay for TCGF75.
Biochemical characterization of IL-2 from mitogen-stimulated human, murine,
and rat lymphocytes soon followed.

Interleukin 2 from human and rat

lymphocytes was found to have a molecular weight (on gel filtration) of
approximately 15,000 daltons76 while murine IL-2 had a molecular weight of
30,000 daltons77. Taniguchi et al. using a cDNA coding for human IL-2 showed
that after processing mature human IL-2 contains 133 amino acids and a
calculated molecular weight of 15,420.5 daltons78. The observation that murine
IL-2 has an apparent molecular weight twice that of human and rat has been
attributed to noncovalent dimerization of a 15,000 dalton subunit79.
The findings that the mitogenic effect of IL-2 was strictly concentration
dependent75 and that T cells activated by either lectins or antigens absorbed IL2 in a cell concentration dependent fashion80 suggested that the binding and
removal of IL-2 might be receptor mediated81.

Robb et al. using internally

radiolabeled IL-2 in a series of competitive binding experiments were the first to
show that IL-2 interacted with activated T cells through a high affinity receptor51.
With the monoclonal antibody anti-Tac Leonard et al. were able to partially
purify and characterize the human IL-2 receptor82. They found that the receptor
was a glycoprotein with a molecular weight of 47,000-53,000 daltons.

Reports
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of monoclonal antibodies directed against murine (7D4, AMT-13)83-84 and rat85
IL-2 receptors soon followed.

Both monoclonal antibodies against the murine

IL-2 receptor precipitated a protein with an apparent molecular weight of
50,000-60,000 daltons; however, only AMT-13 was able to inhibit IL-2 binding.
These results suggest that AMT-13 binds to the active site on the murine IL-2
receptor while 7D4 bind to a distal epitope or possibly another protein that is
physically associated with the IL-2 receptor.

Cloning of a cDNA encoding the

human IL-2 receptor was independently undertaken by Leonard et al.86 and
Nikaido et al.87.

Both groups found two mRNAs hybridzing to the cDNA clone

and a fairly identical sequence. At about the same time Robb et al. reported the
presence of high and low affinity IL-2 receptors88.
the

discrepancy

that

arose

when

This finding helped explain

quantitative

binding

studies

using

radiolabeled IL-2 and anti-Tac indicated that there were far more Tac binding
sites than IL-2 binding sites. Robb et al. found that the low-affinity receptors had
an association constant greater than 5,000 times lower than the initially
described high-affinity receptor.

Robb, in a definitive study which showed the

conversion of low-affinity receptors to high-affinty receptors following fusion of
cell membranes, that the same Tac protein can act either as a high or low
affinity receptor89.

Kondo et al. in an elegant synthesis of the literature on the

IL-2 receptor have proposed that a binary complex between the IL-2 receptor
and another protein would constitute a high-affinity receptor90. In their model, a
high-affinity receptor is the ternary complex of IL-2, the IL-2 receptor, and a
“converter" protein.
Like interleukin 1 IL-2 has a number of roles in the immune response.
Although primarily associated with T cell proliferation, IL-2 also directly or
indirectly plays a role in the proliferation and maturation of other cell types79.
Henney et al. found that IL-2 augmented natural killer activity91.

Mond et al.
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have shown that affinity purified IL-2 caused large B cells to proliferate92.
Howard et al. noted that IL-2 induced certain antigen reactive T cell lines to
secrete low levels of IL-493.

Kasahara et al. using IL-2 were able to induce

peripheral T cells to secrete IFN-y94. And Kelso et al., in a recent report on the
regulation of GM-CSF production, observed that IL-2 preferentially induced
certain T cell clones to secrete only GM-CSF as compared to GM-CSF and IL-3
when stimulated with lectins such as Con A.95
Interleukin 3 (IL-3)

Interleukin 3 is one of two, the other being GM-CSF, colony stimulating
factors which are active on early (pluri- or multipotential) precursors of
hemopoietic stem cells96. It was initially identified as a lymphokine capable of
inducing the enzyme 20a-hydroxysteroid dehydrogenase (a specific marker of
mature T cells) in cultures of the splenic lymphocytes from athymic mice97. In
addition to being secreted constitutively by the myelomonocytic leukemia cell
line WEHI-3, T cells and T cell tumors produce IL-3 upon stimulation98.

Using

WEHI-3-conditioned media Ihle et al. purified IL-3 to apparent homogeneity99.
They noted a molecular weight of 28,000 daltons by gel electrophoresis and an
activity of 1.79 x 10'12 M. Fung et al. using mRNA from WEHI-3 cells were able
to clone and sequence the cDNA coding for murine IL-3100.

Sequence

analysis of the cloned cDNA revealed that it coded for a precursor polypeptide
of 166 amino acids.

Yokata et al. cloning the cDNA for mast-cell growth-factor

found a sequence identical to that of IL-3101.
A broad range of biological activities have been attributed to IL-3
including multi-colony stimulating factor, hematopoietic growth factor, burstpromoting activity, FDC-P cell line stimulating factor, mast cell growth factor,
histamine-producing cell stimulating factor, and Thy 1-inducing activity100.
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Interleukin 4 (IL-4)

The existence of a T cell derived B cell growth factor was first implied
from a study by Howard and her co-workers102.

In that study normal mouse B

cells were propagated with medium supplemented with a T cell-hybridomaderived supernatant.

Howard et al., using a phorbol myristate acetate (PMA)

induced EL-4 supernatant, first identified a B cell growth factor (BCGF) as
distinct from IL-2103.

Ohara et al. using trimethyIsilyHcontrolied pore glass

beads (TMS-CpG) and reverse-phase high-performance liquid chromatography
(RP-HPLC) were able to partial purify IL-4 and noted an apparent molecular
weight of 18,000 and 21,700 daltons when analyzed by isoelectric focusing and
gel filtration-HPLC, respectively104.

Using IL-4 purified in this manner Ohara

and Paul were able to establish a rat-mouse hybridomas that secreted anti-IL-4
antibodies (11B11 and 18F10)105. Grabstein et al. purified IL-4 to homogeneity
and found a molecular weight of 18,400 daltons by gel electrophoresis106. The
cDNA clone that encoded for murine IL-4 was isolated, expressed, and
characterized independently by Noma et al.107 and Lee et al.108.

Both groups

noted that the murine IL-4 gene coded for a precursor polypeptide of 140 amino
acids. Yokota et al. recently characterized the cDNA clone encoding for human
IL-4109.

They found that the human IL-4 gene encoded for a 153 amino acid

polypeptide precursor and that on the genomic level human and murine IL-4
shared extensive homology.

Although there are presently no definitive reports

concerning the IL-4 receptor, Mishra et al. have reported that a monoclonal
antibody directed against the lymphocyte function-associated antigen 1 (LFA-1)
a-chain, a cellular adhesion molecule, mimics some of the biological effects of
IL-4 suggesting that LFA-1 may be the receptor for IL-4 or a receptor-associated
molecule involved in IL-4 cell signaling110.

.
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Interleukin 4 possess a wide variety of biological activities. In addition to
acting synergistically with IL-1 in enhancing proliferation of anti-IgM activated B
cells, Noelle et al. have observed that IL-4 increased expression of class II MHC
products on resting B cells111.

Rabin et al. noted that a preculture with IL-4

sped the entry of those cells into S phase when they were subsequently
cultured with IL-4 and anti-IgM. They also observed that pretreatment of resting
B cells with IL-4 resulted in a substantial increase in cell volume49. Vitetta et al.
found that IL-4 in addition to being a B cell growth factor is also a B cell
differentiation factor112. They noted that IL-4 induced the secretion of IgGI and
inhibited the secretion of lgG3 in lipopolysaccharide (LPS)-stimulated B cells.
Coffman et al. noted a similar finding concerning IgE production113-114. A
recent report by Finkelman et al. concerning the suppression of an in vivo
polyclonal IgE response by the anti-IL-4 antibody 11B11 further supports the
observation made by Coffman et al.115.

In addition to B cells, IL-4 has also

been shown to promote the growth of T helper cell lines50-116, and to act as a
costimulant with PMA on a heterogeneous population of resting T Cells117.
Mosmann et al. have also observed that IL-4 costimulates with IL-3 to increase
the proliferation of certain mast cell lines118.
Granulocyte-Macrophage Colony Stimulating Factor

(GM-CSF)

Like IL-3, GM-CSF is active on early precursors of hemopoietic stem
cells.

Lopez et ai. have recently reported that in addition to stimulating

neutrophil progenitor cells GM-CSF also activates differentiated neutrophils119.
They noted enhanced antibody-dependent, ceil mediated cytotoxicity when
mature neutrophils were cultured with GM-CSF.

Kelso et al. noted another

difference between IL-3 and GM-CSF; whereas, IL-3 is solely secreted by
activated T cells, GM-CSF is also produced by macrophages, fibroblasts, and
endothelial cells95.

Gough et al. using a partial NH2-terminal amino acid
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sequence from purified mouse lung-conditioned medium were able to produce
a cDNA clone which they used to isolate a unique gene encoding for GMCSF120.

They noted that the gene coded for a messenger RNA of 1,200

nucleotides, a polypeptide of 118 amino acids, and had no structural similarity
to 11-3.

In addition to the aforementioned activities, Handman and Burgess

reported that when peritoneal macrophages were treated with GM-CSF they
were able to kill intracellular Leishmania tropica that were hitherto multiplying
within the macrophage121.

Dessein et al. noted eosinophil cytotoxicity was

marked enhanced in the presence of GM-CSF122. Grabstein et al. noted that
GM-CSF potentiated induction of antibody secretion by activating an accessory
function of macrophages123 and induced macrophage tumoricidal activity124.
Finally, Woods et al. have found that GM-CSF can induce proliferation in a
TCGF dependent T cell line125.
Interferon-gamma

(IFN-y)

Interferons are secreted proteins which have immunomodulatory and
antitumor properties126.

There are three major classes of interferons: IFN-a

(leukocyte or fast) , IFN-{3 (fibroblast or slow), and IFN-y (immune)127. Unlike
IFN-a or IFN-p, IFN-y is acid labile, does not cross-react with antisera prepared
against IFN-a or IFN-p, and is generally produced in cultures by mitogenically
stimulating

lymphocytes126.

Using a cDNA clone prepared from gel-

fractionated IFN-y mRNA, Gray et ai. were able to isolate, characterize, and
express the cDNA sequence encoding for the IFN-ygene126. They found that
the DNA coded for a 166 amino acid polypeptide including a 20 amino acids
signal peptide.

Taking this into account Gray et al. calculated that the

processed protein not accounting for post-translatioal modifications had a
molecular weight of 17,110 daltons.
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Interferon-gamma has a broad range of biological activities.

Blalock et

al. noted that IFN-y has both anticellular and antiviral activity128. Catalona et al.
found that IFN-y is a potent stimulator of antibody-dependent cell-mediated
cytotoxicity (ADCC) and of natural killer cytotoxicity129; while, Wallach noted
that IFN-y induced resistance to the killing by NK cells130.

A number of

investigators have all independently shown that IFN-y induces expression of
class II MHC products on macrophages131-132-133 and on endothelial cells134.
Another immunomodulatory function has recently been ascribed to interferon-y.
Coffman and Carty113 and Rabin et al.135 have observed that the IL-4
polyclonal IgE response and the IL-4 response on resting B cells can be
inhibited by IFN-y. Mond et al. have recently shown that IFN-y suppresses the
IL-4 induced augmentation of class II MHC product expression136. Finally,
Grabstein et al. noted that IFN-y also induced peripheral blood monocytes to
exhibit tumoricidal activity against a malignant melanoma cell line124.
Lymphotoxin

(LT)

Lymphotoxin is a lymphocyte derived glycoprotein possessing direct
cytolytic and cytostatic activities for a variety of cells was first described by
Ruddle and Waksman137. They noted that lymph node cells from inbred rats
with delayed hypersensitivity to tuberculoprotein, bovine gammaglobulin, and
egg albumin produced progressive destruction of monolayers of rat embryo
fibroblasts in tissue culture138.

Although some investigators have reported a

number of different molecular weight lymphotoxins139, Gray et al. in cloning and
expressing the cDNA encoding human lymphotoxin reported that lymphotoxin
was encoded by a single gene140.

They found that the lymphotoxin gene

coded for a precursor polypeptide of 205 amino acids which after processing
but before glycosylation was thought to have 171 amino acid and a molecular
weight of 18,600 daltons.
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A number of different biological activities has been ascribed to
lymphotoxin.
proliferation141.

It

has

been

shown to cause

inhibition

of tumor cell

Sawada and Osawa implicated lymphotoxin as the effector

molecule in T cell mediated cellular cytotoxicity142; while, Wright and Bonavida
found that a lymphotoxin-like molecule mediated lysis of natural killer cell
targets143.

However, Green et al. recently readdressed this issue and found

that human cytotoxic T cells produced cytotoxins that were antigenically distinct
from

lymphotoxin144.

Kondo et al. observed that antiserum against

lymphotoxin inhibited ADCC and hence suggested that lymphotoxin was the
mediator of ADCC145.
recently shown

Stone-Wolff et al.146 and Lee et al.147 have both

marked synergistic enhancement of cytotoxicity when

lymphotoxin is added to interferon-y.
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Experimental Hypothesis
The growth and proliferation of mammalian cells are controlled in part by
polypeptide hormones found in the serum148. Malignant or transformed cells
appear to require no or lower concentrations of growth-controlling factor(s) as
compared with normal or untransformed cells148.

It has therefore been

suggested that cells could become malignant via the aberrant production of
polypeptide growth-controlling factor(s) acting in an autocrine manner through
functional cell membrane receptors resulting in uncontrolled proliferation149.
Recently, the “autocrine hypothesis” has been further defined in that malignant
transformation may be the result not only of excessive production, expression,
and action of positive autocrine growth factors but also the failure of cells to
synthesize, express or respond to specific negative growth factors that they
normally release to control their own growth150.
Interleukin 2, originally termed T cell growth factor, has been shown to
promote the proliferation of any IL-2 receptor positive T cell79.

It has been

shown that the T helper cell line DIO apparently secretes large amounts of IL-2
(as determined by its ability to stimulate an IL-2 dependent cell line and by the
observation that its autocrine proliferation is inhibited by a monoclonal anti-IL-2
antibody) upon crosslinking of its antigen-class II MHC products receptor yet
fails to proliferate27-34.

Furthermore, DIO cells have to been shown to both

respond to IL-2 derived from the T cell hybridoma AOFS34 and to express
functional IL-2 receptors27. Thus in the presence of both functional IL-2 and IL2 receptors this clone fails to proliferate.
The goal of the experiments described in this thesis is to determine the
mechanisms involved in this paradox.

The growth factor(s) found in the

stimulated supernatants from DIO cells and AOFS cells will be further
characterized in order to ascertain why these two supernatants have different
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biological activities yet both apparently contain IL~2.

It is possible that the

supernatant from the transformed cell line contains a growth-factor(s) that
is(are) absent from the normal cell lines' supernatant.

Likewise, it is possible

that the DIO supernatant has a negative growth-factor(s) absent from the AOFS
supernatant that prevents its uncontrolled proliferation.
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Materials and Methods
Animals. The mice used in these experiments, BALB/cByJ and AKR/J,
were obtained from The Jackson Laboratory.

Cloned T-Cell Lines. The AKR/J cloned T-cell line D10.G4.1 (DIO) has
been described extensively23-24-27-34.

It is specific for the hen white protein

conalbumin (Sigma Chemical Co. St. Louis, MO) in the context of l-Ak and also
responds to the monoclonal anti-T cell receptor antibody 3D3 (see below). The
BALB/cByJ cloned T cell lines 5.5 and 5.9.24 have been described in detail
elsewhere151-152-153.

They are specific for hen ovalbumin (Sigma Chemical

Co. St. Louis, MO) and l-Ed or l-Ad, respectively. These cloned T cell lines were
maintained at 37°C in a 5% C02 atmosphere by feeding with syngeneic
mitomycin C-treated spleen cells and specific antigen (100 pg/ml) every one to
three weeks in Click's EHAA medium154 (Irvine Scientific, Santa Ana, CA)
supplemented with 10% fetal bovine serum (Irvine Scientific, Santa Ana, CA)
and 5% TCGF-containing supernatant of concanavalin A (Con A) (Pharmacia
Inc., Piscataway, NJ)-treated rat spleen cells155. Between feedings with spleen
cells and antigen, the T cell lines were fed at intervals with the same medium.

Antibodies. Monoclonal murine IgGI anti-DI0-receptor antibody (3D3).
The monoclonal antibody was produced and assayed as described34.

It was

used as a saturated ammonium sulfate (SAS) precipitated, Protein A purified
diluted ascitic fluid.

Monoclonal rat

IgGI

anti-murine-BSF- 1/IL-4

antibody

(11B11).

Hybridoma cells were a kind gift from J. Ohara and W. E. Paul (National
Institutes of Health, Bethesada, MD) and this antibody has been extensively
described elsewhere105. Antibody was used as a SAS precipitated ascitic fluid
at a final concentration of 1: 200.
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Monoclonal rat lgG2a anti-murine-IL-2 antibody (S4B6). Hybridoma cells
were a kind gift from T. Mosmann (DNAX Research Institute of Molecular and
Cellular Biology, Palo Alto, CA) and this antibody has been extensively
elsewhere118.

Antibody was used as serum-free culture supernatant at a final

concentration of 1: 4 unless otherwise noted.

Culture Supernatants. Interleukin 1

Murine IL-1 was prepared as

described27 by stimulating the murine macrophage cell line P388.D1 with
1pg/ml of lipopolysaccharide (Difco Labs, Detroit, Ml) for twenty-four hours.

Recombinant-derived murine IL-1 a. Murine IL-1 a was a kind gift of S.
Gillis (Immunex Corp. Seattle, WA).

Recombinant-derived human IL-2.

Human IL-2 was purchased from

AMGen Biologicals (Thousand Oaks, CA).

Recombinant-derived murine IL-2 Murine IL-2 was a kind gift of S. Gillis
(Immunex Corp. Seattle, WA).

Affinity purified BSF-1/IL-4.

A high titered,

BSF-1/IL-4 containing

supernatant was kindly provided by L. Greenbaum (Yale University School of
Medicine, New Haven, CT).

Briefly, DIO cells were incubated for twenty-four

hours at a concentration of one million cells per milliliter in serum-free EHAA
medium containing 1% HB101 (Hara Medium, Berkeley, CA) and 2.5pg/ml of
Con A.

Supernatants were collected and passed over an anti-BSF-1 /IL-4

affinity column. The bound material was eluted with 0.1% trifluoracetic acid.

Its

biological activity was inhibited by a monoclonal anti-BSF-1/IL-4 antibody.

Recombinant-derived murine Interferon-y. Murine IFN-y was a kind gift of
the Genentech Inc. (San Francisco, CA).

AOFS supernatants. The T cell hybridoma AOFS 21.10.9 was kindly
donated by P. Marrack and J. Kappler (National Jewish Hospital, Denver, CO).
Supernatants were obtained by incubating cells at an initial concentration of 5
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xIO5 cell/ml with 2.5pg/ml of Con A in EHAA medium lacking serum for twentyfour hours.

Con A Supernatants were then collected, filtered over a 0.22pm

millipore filter (Millipore Corp., Bedford, MA).and neutralized with 20mg/ml of
methyl a-D-mannoside (Sigma Chemical Co., St. Louis, MO).

DIO supernatants/inhibitor supernatants.

DIO cells at one hundred

thousand (105) cells per milliliter were stimulated for twenty-four hours in Click’s
EHAA medium containing 5% serum with either the monoclonal anti-receptor
antibody 3D3 at 20ng/ml or Con A at 2.5pg/ml. Supernatant were collected and
flitered over a 0.22pm millipore filter, and the Con A supernatants were
neutralized with 20mg/ml of methyl a-D-mannoside.

All assay using such

supernatants contained 5mg/ml of methyl a-D-mannoside.

Unless referred to

otherwise 3D3 was used to generate the supernatants.

Bioassays. Proliferation assays. Cells plus supernatants were incubated
together in either lOOpI or 200pl volumes of Click's EHAA/5% fetal bovine
serum in flat-bottom 96 well trays. After culture for twenty of forty-four hours at
37°C in a 5%C02 atmosphere, 1 pCi (1 Ci= 37GBq) of tritiated-thymidine was
added to each microculture.

Four hours later, cells were harvested with a PHD

harvester (Cambridge Technologies, Cambridge, MA), and incorporated
tritiated-thymidine of triplicate cultures were determined. Standard deviations of
mean CPM incorporated were <20% and have been omitted.

IL-1 assay. IL-1 was assayed as previously described by comitogenesis
of DIO cells and 3D327.

Such supernatants caused no growth of DIO in the

absence of and were without activity in the TCGF assay.

TCGF assay.

IL-2

and/or

IL-4 was

assayed

by

measuring

the

incorporation of tritiated-thymidine by the TCGF-dependent T helper cell line
HT-2, initially described by Watson156. After twenty hours, microcultures of 104

■
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cells were incubated for four hours with IpCi

of tritiated-thymidine and

subsequently harvested and mean CPM of triplicate cultures determined.

Inhibitor assay.

Inhibitor containing supernatants were incubated for

forty-eight hours with twenty thousand (2 x 104) 5.5 cells in the presence of 0.5
units of recombinant IL-2. Proliferation was measured by pulsing with 1 jiCi/well
of tritiated-thymidine for the final four hours of the assay.

Cells were

subsequently harvested and mean CPM of triplicate cultured determined.
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Results
The cloned murine T helper cell line DIO has previously been shown to
secrete large amounts of a T cell growth factor (TCGF) when stimulated with a
monoclonal antibody (3D3) specific to its T cell receptor complex27.

DIO cells

have also been shown to proliferate in response to an IL-2 rich AOFS
supernatant34 and to recombinant IL-2.

Flowever, when DIO cells are

stimulated with 3D3 they fail to proliferate unless IL-1 is also added to the
cultures (Table I).

To further explore this observation, DIO cells were cultured

with recombinant IL-2 and with a 3D3 stimulated DIO supernatant.

As noted in

Table 1, DIO cells only proliferated in response to recombinant IL-2.

Given

these paradoxical findings, the following experiments were performed in order
to explain this phenomenon.

Both DIO Supernatant and AOFS Supernatant Have TCGF Activity.
When DIO cells are stimulated with 3D3 in a twenty-four hour culture they
secrete a factor(s) which has TCGF activity as measured by bioassay of the
supernatant on the TCGF dependent cell line HT-2 (Fig. 1). Likewise, when the
T cell hybridoma AOFS is stimulated with the mitogenic lectin Con A a twentyfour hour supernatant also stimulates the proliferation of HT-2 cells. Thus, DIO
supernatant and AOFS supernatant contain a factor(s) possessing TCGF
activity.

AOFS Supernatant Contains IL-2 and IL-4 While DIO Supernatant
Contains Only IL-4. The preceding experiment revealed that both supernatants
had TCGF activity.

Given that HT-2 cells respond to both IL-2106, IL-450, and

GM-CSF125 it was necessary to determine which factor(s) in each supernatant
was causing the growth of the HT-2 cells.

Using monoclonal antibodies with

specificities against either IL-2 (Table II) or IL-4 each supernatant was tested.
(Presently, there

are

no

monoclonal

antibodies specific for GM-CSF).

Table I. Both DIO and HT-2 Cells Proliferate in Response to Recombinant IL-2
While Only HT-2 Cells Proliferate in Response to DIO Supernatant.
D101

HT-22

1030

563

+3D33

3096

-

+IL-14

1742

-

+3D3+IL-1

53058

+RIL-25

36987

178610

3903

97402

Stimulus
-

+3D3-stimulated D10 S/N6

-

1D10 cells at 20,000 cells/well were incubated in triplicate culture in the
presence of the above stimuli for forty-eight hours. Proliferation was measured
by pulsing with tritiated thymidine for the last four hours of the assay. Mean
±SD (omitted from table) were calculated for each triplicate culture.
2HT-2 cells at 10,000 cells/well were incubated in triplicate culture in the
presence of the above stimuli for twenty-four hours. Proliferation was measured
by pulsing with tritiated thymidine for the last four hours of the assay. Mean
±SD (omitted from table) were calculated for each triplicate culture.
320ng/ml of 3D3.
435 P388D1 IL-1 rich supernatant.
55.0 units of recombinant IL-2.
6D10 cells at 105 cells/ml were stimulated with 20ng/ml of 3D3 for twenty-four
hours. Supernatant (S/N) was collected, filtered, and used at a concentration of
50%.
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Proliferation of HT-2 (ACPM)

Figure: 1

-tr

AOFS S/N
D10 S/N

Supematant Concentration, %

Figure 1: HT-2 cells at 10,000 cells/well were incubated in
triplicate culture for twenty-four hours with varying
concentrations of TCGF containing supernatants.
Proliferation was measured by pulsing for the last four
hours of the assay with lpCi/well of tritiated thymidine.
Mean ±SD (<20%, omitted from figure) was calculated
for each triplicate culture.
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Table II. The Monoclonal Antibody S4B6 Inhibits the Proliferative Response of
HT-2 Cells to Recombinant Murine Interleukin 2.
Concentration of RIL-2

Control

+S4B6

1.25 Units

50060

37174

0.08 Units

2268

137

HT-2 cells at 10,000 cells per well were incubated in triplicate culture for twentyfour with murine recombinant IL-2 in the presence or absence of a 1:2 dilution of
S4B6 culture supernatant.
Proliferation was measured by pulsing with
IjiCi/well of tritiated thymidine for the last four hours of the assay. Mean ± SD
(<20%, omitted from table) was calculated for each triplicate culture. Response
reported in ACPM.
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Treatment of the AOFS supernatant with either the monoclonal antibody to IL-2
or to

IL-4 resulted in decreased proliferation by the HT-2 cells (Fig. 2). When

treated with both antibodies together the TCGF containing activity in the AOFS
supernatant was essentially removed. When the DIO supernatant was cultured
with the same panel of monoclonal antibodies, only treatment with the
monoclonal

antibody

specific to

murine

IL-4

proliferative response by the HT-2 cells (Fig. 3).

resulted

in

a decreased

Quantification of the TCGF

activity in the AOFS supernatant revealed that it contained 25 units/ml of IL-2
and approximately 8 units/ml of IL-4; while, the TCGF activity of DIO
supernatant was due to the presence of about 45 units/ml of IL-4. In summary,
AOFS supernatant contains both
only

IL-2 and IL-4 while DIO supernatant contains

IL-4.
DIO Supernatant Fails To Induce Proliferation of DIO Cells. Given that

both the AOFS supernatant and the DIO supernatant caused the T helper cell
line

HT-2 to proliferate, the question as to whether both supernatants could

cause growth in another T helper cell line was readdressed.

Both an AOFS

supernatant and a DIO supernatant were titrated on Di0 cells.

The AOFS

supernatant caused proliferation on DIO that approached background when
diluted (Fig. 4).

On the other hand, DIO supernatant which caused analogous

proliferation to that of the AOFS supernatant of HT-2 cells induced only minimal
proliferation of DIO cells (Table I and Figs. 1 and 4).

In summary, although DIO

supernatant contains a T cell growth factor it nonetheless failed to induce a
proliferative response on DIO cells.
The question that naturally arises from these observations is: what
prevents the TCGF found in DIO supernatant from acting upon DIO cells?

A

preliminary answer emerges when one closely examines the effects on DIO
supernatant on DIO cells.

At high concentrations DIO supernatant does not
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Proliferation of HT-2 (ACPM)

Figure: 2

-Q-

AOFS

__f_

+11B11

_X_

+S4B6
+(11B11&S4B6)

AOFS Supernatant (% Cone.)

Figure 2: HT-2 cells at 10,000 cells/well were incubated in
triplicate culture for twenty-four hours with varying
concentrations AOFS supernatant in the presence or
absence of a variety of monoclonal antibodies. 1 IB 11 is a
monoclonal antibody with specificity against murine
BSF-l/IL-4. S4B6 is a monoclonal antibody with
specificity against murine IL-2. Proliferation was
measured by pulsing for the last four hours of the assay
with lpCi/well of tritiated thymidine. Mean ±SD (<20%,
omitted from figure) was calculated for each triplicate
culture.
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Proliferation of HT-2 (ACPM)

Fiaure:3

-O-

DIO S/N
+11B11

-*■

DIO S/N (% Cone.)

Figure 3: HT-2 cells at 10,000 cells/well were incubated in
triplicate culture for twenty-four hours with varying
concentrations D10 supernatant in the presence or absence
of a variety of monoclonal antibodies. 1 IB 11 is a
monoclonal antibody with specificity against murine
BSF-l/IL-4. S4B6 is a monoclonal antibody with specificity
against murine IL-2. Proliferation was measured by pulsing
for the last four hours of the assay with lpCi/well of
tritiated thymidine. Mean ±SD (<20%, omitted from figure)
was calculated for each triplicate culture.

+S4B6
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Proliferation of DIO (ACPM)

Figure: 4

HD-

AOFS S/N
D10 S/N

Supernatant Concentration, %

Figure 4: DIO cells at 20,000 cells/well were incubated in
triplicate culture for forty-eight hours with varying
concentrations of TCCF containing supernatants.
Proliferation was measured by pulsing for the last four
hours of the assay with lpCi/well of tritiated thymidine.
Mean ±SD (<20%, omitted from figure) was calculated
for each triplicate culture.
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cause substantial growth of DIO cells; however, when the supernatant is diluted
DIO cells begin to show an increasing proliferative response. These findings
suggest that there is an inhibitor in DIO supernatant which is not present in
AOFS supernatant that prevents autocrine stimulation.
DIO Supernatant Inhibits the Response of Other Cloned T Cell Lines to
IL-2. In order to determine whether the inhibitory nature of DIO supernatant
was unique to the DIO cell line other T helper cell lines were tested for their
ability to respond to DIO supernatant, recombinant IL-2, and a mixture of both.
The BALB/c cloned T cell line 5.5 responds well to recombinant IL-2 but not to
DIO supernatant (Fig. 5).

Furthermore, DIO supernatant significantly inhibits

the response of these cells to recombinant IL-2. Analogous results were seen
with another BALB/c T cell clone 5.9.24 (Fig. 6). In summary, DIO supernatant
can significantly inhibit the proliferative response to recombinant IL-2 on a
number of different T helper cell lines.
These experiment further defined some of the cellular properties of the
inhibitory factor (s) in DIO supernatant. (For simplicity, the inhibitory factor (s) in
DIO supernatant shall now be referred to as Inhibitor). Given that 3D3 does not
react specifically with either 5.5 or 5.9.24, and that analogous results were
obtained whether DIO was stimulated with either 3D3 or Con A (data not
shown), the inhibitory substance is not 3D3. Furthermore, as the T helper cell
clones DIO and 5.5 differ in antigen specificity and MHC restriction, and are
derived from mice differing at MHC and other loci, Inhibitor is apparently not
genetically restricted in its action on other cells and thus is distinct from most
known suppressor factors.
Secretion of Inhibitor by DIO is Stable Over Time. To determine whether
or not secretion of Inhibitor was the result of transient cell culturing conditions,
the experimental protocol was repeated periodically over a time span of
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Figure: 5
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Proliferation of 5.5 (ACPM)
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0
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12.5%

50%

Inhibitor (Cone.)

Figure 5: 5.5 cells at 20,000 cells/well were incubated in
triplicate culture for forty-eight hour with varying concentrations
of Inhibitor supernatant in the presence or absence of 0.5 Units
of recombinant IL-2. Proliferation was measured by pulsing
with IpCi of tritiated thymidine for the last four hours of the
assay. Mean ±SD (<20%, omitted from figure) was calculated
for each triplicate culture.
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Proliferation of 5.9 (ACPM)

Figure: 6

-O-

INH S/N

X=0.5U RIL-2

Inhibitor Supernatant (Cone.)

Figure 6: 5.9 cells at 20,000 cells/well were incubated in
triplicate culture for forty-eight hours with varying
concentrations of Inhibitor supernatant in the presence of 0.5
Units of recombinant IL-2. Proliferation was measured by
pulsing with IpCi/well of tritiated thymidine for the last four
hours of the assay. Mean ±SD (<20%, omitted from figure)
was calculated for each triplicate culture.
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approximately three years.

Although the responsiveness of 5.5 cells to

recombinant IL-2 has apparently changed Inhibitor can still significantly inhibit
the proliferative response to IL-2 on the 5.5 cells (Fig. 7). Thus Inhibitor was not
the result of transient cell culturing conditions.

Interferon-y is Not Inhibitor. As previously discussed, IFN-y has both
immunoregulatory and anticellular activities. Given that both Inhibitor and IFN-y
have apparent antiproliferative properties and are T helper cell products it was
necessary to determine whether Inhibitor is IFN-y.

A titration of recombinant

IFN-y in the presence of recombinant IL-2 did not result in diminution of the IL-2
proliferative response (Fig. 8).

This observation combined with those of

Mosmann et al.44 and Killar et a!.46 that IL-4 producing T helper cell lines do not
secrete IFN-y provides definitive evidence that Inhibitor is not IFN-y.

Interleukin 4 is Not Inhibitor. It may be argued that on theoretical grounds
IL-4 may be the Inhibitor.

Given that IL-2 and IL-4 both activate HT-2 cells it is

possible (although not probable) that they use the same or similar receptors.
This being correct, it would not be unreasonable to assume that these ligands
would have different affinities for this presumed receptor.

If so, IL-4 binding this

presumed receptor may not result in activation but may occupy binding sites
such that IL-2 can not signal the cell.

Therefore, if the concentration of IL-4 is

much higher than that of IL-2, IL-4 may act as an inhibitor of IL-2. To determine
the plausibility of this assumption varying concentrations of IL-4 were cultured
with IL-2 (Fig. 9). The results here show that IL-4 synergizes with IL-2 resulting
in the proliferation of 5.5 cells. The finding of Robb et al.51 that the IL-2 receptor
has a very high affinity for IL-2 and the observation by Ohara and Paul105 that
anti-IL-2 receptor antibodies failed to block the biological activity of IL-4,
combined with the results from this experiment strongly suggest that IL-4 is not
Inhibitor.
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Proliferation of 5.5 (ACPM)

Figure: 7

_Q_

INH S/N

X=0.5U RIL-2

Figure 7: 5.5 cells at 20,000 cells/well were incubated in
triplicate culture for forty-eight hour with varying
concentrations of Inhibitor supernatant in the presence of 0.5
Units of recombinant IL-2. Proliferation was measured by
pulsing with lpCi of tritiated thymidine for the last four hours
of the assay. Mean ±SD (<20%, omitted from figure) was
calculated for each triplicate culture.
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Proliferation of 5.5 (ACPM)

Figure: 8

-0-

ifn -y
+RIL-2

X=0.5U RIL-2

Figure 8: 5.5 cells at 20,000 cells/well were incubated in
triplicate culture for forty-eight hour with varying
concentrations of recombinant interferon- gamma in the
presence or absence of 0.5 Units of recombinant IL-2.
Proliferation was measured by pulsing with lpCi/well of
tridated thymidine for the last four hours of the assay. Mean
±SD (<20%, omitted from figure) was calculated for each
triplicate culture.
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Proliferation of 5.5 (ACPM)

Ei&umLa

BSF-l/EL-4
+RIL-2

x= •0.5U RIL-2

BSF-l/IL-4 (dilution of stock solution)

Figure 9: 5.5 cells at 20,000 cells/well were incubated in
triplicate culture for forty-eight hour with varying concentrations
of affinity purified BSF-l/IL-4 in the presence or absence of
0.5 Units of recombinant IL-2. Proliferation was measured by
pulsing with l|iCi/well of tritiated thymidine for the last four
hours of the assay. Mean ±SD (<20%, omitted from figure)
was calculated for each triplicate culture.
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DIO Expresses Functional IL-1 Receptors. Kaye et al.34 noted that when
DIO cells were stimulated with 3D3, the presence of either accessory cells or IL1 was necessary to insure cellular proliferation. This observation led Kaye et al.
to propose that two distinct events, namely receptor cross linking and
stimulation with IL-1, must take place in order for cellular proliferation to occur.
The question that logically follows from this is: by what mechanism does
receptor cross linking and stimulation with IL-1 lead to proliferation of DIO? As
shown in Table I and Fig. 3, activation of DIO in the absence IL-1 results in
secretion of IL-4 but no growth and IL-1
proliferate.

alone does not induce DIO to

However, if DIO cells are cultured in the presence of both DIO

supernatant (as a source of IL-4) and IL-1 proliferation occurs (Fig. 10). In order
to rule out the possibility that this proliferation was due to carryover 3D3, an
identical experiment using a Con A induced DIO supernatant was performed.
Analogous findings were noted (data not shown), thus proliferation was not
caused by carryover 3D3 but the result of synergy between IL-1 and the
factor(s) found in DIO supernatant.

In a similar experiment done by Dr. C.

Janeway, preculture of DIO cells with IL-1
stimulation also resulted in proliferation.

followed by subsequent 3D3

The conclusions to be drawn from

these experiments are that the factor(s) contained in DIO supernatant and IL-1
are synergistic on DIO cells, and that under its current cell culturing conditions
DIO expresses functional IL-1 receptors.
Autocrine Proliferation of DIO is an IL-4 Mediated Process. The finding
that DIO supernatant caused HT-2 cells to proliferate, combined with the
observation that the proliferative response of DIO to 3D3 and IL-1 was greatly
reduced by a monoclonal antibody with a reported specificity against murine IL2,

led to the conclusion that DIO secreted IL-227-34.

However, using

monoclonal antibodies with more clearly defined specificities against murine IL-

.
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Proliferation of DIO (ACPM)

Figure: 10

-Q-

INH S/N
+IL-1

Figure 10: DIO cells at 20,000 cells/well were incubated in
triplicate culture for forty-eight hours with varying
concentrations of Inhibitor supernatant in the presence or
absence of an IL-I rich P388D.1 supernatant. Proliferation
was measured by pulsing for the last four hours of the assay
with IpCi/well of tritiated thymidine. Mean ±SD (<20%,
omitted from figure) was calculated for each triplicate
culture.
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2 and IL-4, it was determined that DIO supernatant contains only 11=4 (Fig. 3)
and that the proliferative response of DIO to 3D3 and IL-1 was IL-4 and not IL-2
mediated (Table III). Thus, the autocrine proliferation of DIO is an IL-4 mediated
process.
Interleukin 1 Augments the Response of DIO to IL-4.

Given that

autocrine proliferation in the DIO system is IL-4 mediated and that DIO
supernatant and IL-1 are synergistic on DIO it appears that IL-1 is necessary for
optimum IL-4 function.

To test this hypothesis DIO cells were incubated with

various concentrations of affinity purified IL-4.

In the absence of recombinant

murine IL-1 minimal proliferation of DIO occurred (Fig. 11).

Flowever, when

affinity purified IL-4 was cultured in the presence of recombinant murine IL-1
there was substantial proliferation of DIO.

To test whether the proliferation of

DIO was due to IL-4 and not some other factor a monoclonal antibody with
specificity against murine IL-4 was used as an internal control. As shown in Fig.
11 the proliferation of DIO was substantially diminished in the presence of the
antibody. An appealing explanation for this observation is that IL-1 is necessary
for the expression of IL-4 receptors.
Interleukin 1 Augments Response of HT-2 to IL-4.

Given that FIT-2 cells

respond to IL-450 and the observation that IL-1 augments the response to IL-4, it
was thought that IL-1 also may augment the IL-4 response on the HT-2 cell line.
As shown in Fig. 12 HT-2 cells behave analogously to DIO.

Thus, IL-1

augments the response of HT-2 cells to IL-4.
Interleukin 1 Augments the Response of DIO But Not HT-2 to IL-2.
et al.27 have previously shown that IL-1
expression on DIO.

Kaye

is necessary for IL-2 receptor

Figure 13 shows that IL-1 augments the response of DIO

cells to IL-2, thus confirming the finding of Kaye et al. Figure 13 also shows that
the anti-IL-4 antibody 11B11 inhibits the proliferative response of DIO to IL-1

\
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Table III. Proliferation of the Cloned Helper T Cell Line D10 is an Interleukin 4
not an Interleukin 2 Mediated Process.
DIO1

3D32

IL-13

+

-

-

-

-

122

943

2711

+

+

-

-

-

871

1704

8636

+

-

+

-

-

1049

3672

7331

+

+

+

-

-

14643

59548 49040

+

+

+

+

-

12814

57850 47100

+

+

+

-

+

anti-IL-24

anti-IL-45
Expt#1

3165

Response6
2
3

6034

23762

1 2 x 104 cells/well.
2 20ng/ml of 3D3.
3 3% P388D1 IL-1 rich supernatant.
4 S4B6 (anti-IL-2) at 1:4 culture supernatant.
5 11B11 (anti-IL-4) at 1:200 SAS cut ascites.
6 Mean CPM of tritiated thymidine incorporation of triplicate cultures, pulsed for
the last 4 hours of a 48 hour assay.
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Proliferation of DIO (ACPM)

Fiaure:11

-O

BSF-l/IL-4
+RIL-1
+RIL-1 &11B11

X=IL-1

Figure 11: DIO cells at 20,000 cells/well were incubated in
triplicate culture for forty-eight hours with varying
concentrations of affinity purifird BSF-l/IL-4 in the
presence or absence of recombinant murine IL-1 (RIL-1)
and in the presence of RIL-1 and 11B11. 1 IB 11 is a
monoclonal antibody with specificity against BSF-l/IL-4
Proliferation was measured by pulsing for the last four
hours of the assay with lpCi/well of tritiated thymidine.
Mean ±SD (<20%, omitted from figure) was calculated for
each triplicate culture.
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Proliferation of HT-2 (ACPM)

Figure: 12

-Q-

BSF-l/IL-4
+IL-1

Figure 12: HT-2 cells at 10,000 cells/well were incubated in
triplicate culture for twenty-four hours with varying
concentrations of affinity purified BSF-l/IL-4 in the presence
or absence of an IL-1 rich P388D.1 supernatant. Proliferation
was measured by pulsing for the last four hours of the assay
with lpCi/well of tritiated thymidine. Mean ±SD (<20%,
omitted from figure) was calculated for each triplicate culture.
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Proliferation of DIO (ACPM)

Figure:-! 3

-0-

RIL-2
+RIL-1
+RIL-1 &11B11

X=RIL-

Recombinant IL-2 (Units)

Figure 13: DIO cells at 20,000 cells/well were incubated
in triplicate culture for forty-eight hours with varying
concentrations of murine recombinant IL-2 (RIL-2) in
the presence or absence of recombinant murine IL-1
(RIL-1) and in the presence of RIL-1 and 11B11.
1 IB 11 is a monoclonal antibody with specificity against
BSF-l/IL-4 Proliferation was measured by pulsing for
the last four hours of the assay with lfiCi/well of
tritiated thymidine. Mean ±SD (<20%, omitted from
figure) was calculated for each triplicate culture.
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plus IL-2. A possible explanation for this observation is that IL-2 causes DIO to
secrete IL-4 which in turn accounts for part of the proliferative response. This is
similar to the observation of Howard et al.93 who noted a similar finding with
their antigen reactive T cell clones.

Interleukin 1 does not augment the

response of HT-2 cells to IL-2 (Fig. 14).

A likely explanation for this

phenomenon is the fact that HT-2 cells constitutively express a very high
number of high affinity IL-2 receptors (R. Robb, personal communication).

■

I
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Proliferation of H i -2 (ACPM)

Figure: 14

IL-2
+ IL-1

Figure 14: HT-2 cells at 10,000 cells/well were incubated in
triplicate culture for twenty-four hours with varying
concentrations of recombinant IL-2 in the presence or absence
of an IL-1 rich P388D.1 supernatant. Proliferation was
measured by pulsing for the last four hours of the assay with
ljlCi/well of tritiated thymidine. Mean ±SD (<20%, omitted
from figure) was calculated for each triplicate culture.
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Discussion
The cloned murine T helper cell line D10.G4.1 was initially described by
Kaye et al. 34.

They noted that stimulation with an anti-receptor monoclonal

antibody resulted in secretion of lymphokines including a factor with TCGF
activity. Further characterization of this factor revealed that it caused the TCGF
dependent line HT-2 to proliferate.

In addition, the anti-IL-2 antibody prepared

by Gillis and Henney157 was shown to inhibit the proliferation of DIO in
response to 3D3 and IL-127.

Taken together these observations provided

convincing evidence that stimulation of DIO resulted in the release of IL-2.
However, evidence to the contrary soon followed.

Using an anti-IL-2 antibody

prepared by Smith et al.158 it was observed that the TCGF activity of DIO
supernatant could not be inhibited while that of AOFS supernatant could (JBH,
unpublished observations).

This finding combined with those presented here

that the TCGF activity in DIO supernatant can be blocked by monoclonal
antibodies to IL-4 but not to IL-2 strongly suggests that the TCGF activity in DIO
supernatant is due to IL-4 and not IL-2.

We are currently using probes for IL-

2mRNA and IL-4mRNA to definitively determine that DIO does not produce IL-2.
These findings also suggest that the antibody produced by Gillis and Henney
might not have been an anti-IL-2 antibody but in actuality may have been an
anti-IL-4 antibody.
The paradox of why DIO to fails to proliferate in response to high levels
of TCGF was also examined.

The finding that a diluted DIO supernatant

caused a greater proliferative response than a more concentrated one
suggested one reason that DIO did not proliferate in response to high levels of
TCGF was due to the presence of an inhibitor.

It appeared that the inhibitory

effect of this factor could be overcome by adding IL-1.

The observations that

DIO supernatant inhibited the response of other cell lines to IL-2 further
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supported this notion.

Partial purification of this factor by Horowitz et al.159

revealed that it was heat and acid stable and had a molecular weight of
approximately 12,000 daltons.

It was also noted that purification of Inhibitor

significantly increased its inhibitory action. As shown here Inhibitor is not IFN-y
nor is it IL-4.

Given that DIO does not secrete lymphotoxin160, Inhibitor is not

lymphotoxin.

The observation that IL-1 can reverse can the action of Inhibitor

makes it highly unlikely the Inhibitor is the so-called “inhibitor of DNA synthesis”
described by Namba and Waksman161.

They found the action of their factor

completely irreversible by thirty hours while in the presence of IL-1 and DIO
supernatant DIO cells are synthesizing DNA, as measured by incorporation of
tritiated-thymidine, forty-eight hours after initial exposure to Inhibitor.
A number of other investigator have reported the existence of factors
inhibiting

il-2162'163,164,165_

Hardt et al. reported the presence of an IL-2

inhibitor in the sera of normal mice but not in the sera of athymic mice162. They
found this inhibitor to be neither antigen specific nor MHC restricted.
addition, they noted of molecular weight of about 50,000 daltons.

In

Although the

biologic activity of this IL-2 inhibitor is similar to Inhibitor it differs in that in it
appeared to be produced by Lyt-23+ cells and it had an apparent molecular
weight of 50,000 daltons.
Kramer and Koszinowski found that Con A activated spleen cell
produced IL-2 and factor(s) that inhibited proliferation of T cells to alloantigen
and the generation of cytotoxic T cells from their precursors163.

Their factor

also inhibited the release of IL-2 from T cells; however, it did not affect the IL-2
mediated growth of T cell blasts. Given that Inhibitor activity is measured by its
ability to suppress proliferation due to IL-2 it is most unlikely that their factor and
Inhibitor are the same.

■

50
A factor that was secreted by cultured glioblastoma cells and was
capable of inhibiting the response of cloned T cells line to IL-2 in addition to
inhibiting the proliferation of a neuroblastic cell line whose growth was not IL-2
dependent was reported by Fontana et al.164.

They also noted a molecular

weight of 97,000 daltons. The fact that this factor inhibited the proliferation of a
cell line that was not IL-2 dependent suggests that this factor may be a non¬
specific growth suppressor. This combined with its high molecular weight argue
against this molecule and Inhibitor being the same.
Lastly, Honda et al. have recently described an IL-2 inhibitor produced by
Con A stimulated spleen cells165.

They found that it was produced by Ly-1 +

and Ly-2+ T cells. Additionally, they noted that it had a molecular weight of
10,000 to 12,000 daltons and that no inhibitor activity could be detected in the
supernatants of Con A stimulated spleen cells until day three.

Although

Inhibitor and this factor have similar molecular weights they differ in that differ
markedly in their release kinetics; Inhibitor secretion occurs shortly (within
twenty-four hours) after stimulation of D10 while Honda et al. find no detectable
inhibitor activity until day three post stimulation.

However, it is possible that the

differences in release kinetics are due to the fact that D10 is not a resting T cell.
Whether these two factors are the same or different remains unknown.
The existence of an inhibitor to IL-2 is not surprising
explain why

In fact it would help

in vivo IL-2 is only effective in close proximity to the secreting cells.

Furthermore, it seems logical that a system, like the immune system, which
depends upon rapid and specific activation of only a very limited number of
cells would secrete factors that activate and inhibit other immune cells.

Liao et

al. recent description an inhibitor of IL-1 in the urine of febrile patients would
support this contention166. The finding that D10 does not secrete IL-2 but IL-4
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raises the question of what role Inhibitor plays in IL-4 mediated proliferation.
This question is currently being investigated.
The finding that the IL-4 dependent cell line DIO requires IL-1 in order to
proliferate in response to IL-4 although not directly made by Kaye et al. could
have been implied from their previously published reports27-43.

As previously

noted, Kaye et al. reported that when DIO cells are stimulated with 3D3 and IL-1
there is at least a ten-fold increase in 7D4 binding protein expressed on the cell
surface as analyzed by FACS.

Using radiolabeled IL-2 it was determined that

IL-1 results in a two-fold increase in high affinity IL-2 receptors (R. Robb and
JBH, unpublished observations).

Thus, IL-1 has definitively been shown to

increase the number of high affinity IL-2 binding sites on DIO.

Given that DIO

does not secrete IL-2 the question that naturally arises is: what function do the
high affinity IL-2 receptors have on DIO?

The observation that stimulation of

DIO with IL-2 results in secretion of IL-4 in addition to proliferation provides at
least a partial answer to that question. Although the relative contributions of IL2 and IL-4 on DIO proliferation is difficult to determine, it appears that IL-2
results in at least some degree of proliferation independent of IL-4.
The observations that IL-4 mediated proliferation is augmented by or
requires IL-1 differs from those made by Hu-Li et al.116. Using a heterogeneous
population of resting T cells from peripheral lymph nodes they found that PMA
along with IL-4 were comitogenic for resting T cells.

They noted that neither

PMA nor IL-4 resulted in the proliferation of resting T cells, that IL-1 did not
synergize with either PMA or IL-4 to result in T cell proliferation, and that T cells
precultured with either PMA or IL-4 failed to respond to subsequent culture with
PMA or IL-4 but did respond subsequent culture with both PMA and IL-4.
Although these observations appear incompatible with the aforementioned
finding that IL-1 is required for or augments IL-4 mediated proliferation they may
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not actually be so. The finding that IL-1 and IL-4 are not comitogenic for resting
T cells is not surprising.

Currently there are no published reports suggesting

that resting T cells express functional receptors for IL-1. Because of its ability to
replace accessory cells in Con A induced IL-2 secretion and IL-2 receptor
expression

by

L3T4+T cells, PMA at lOng/ml is considered by some

investigators to be functionally equivalent to IL-1167.

If this assumption is

correct, it is possible that the reason why IL-4 and PMA are synergistic for
resting T cells is that PMA is acting as an IL-1 analog, and thus increasing IL-4
receptor expression.

The observation by Hu-Li et al. that resting T cells

pretreated with PMA fail to proliferate when subsequently treated with IL-4 is
also contrary to our findings. Given that they pretreated their T cells with 1 ng/ml
of PMA and used a ten-fold higher concentration of PMA in their IL-4 plus PMA
costimulation experiments, it is possible that at a concentration of 1 ng/ml PMA
does not act as an IL-1 analog. Taking all of the above into consideration, the
findings of Hu-Li et al. are not necessarily inconsistent with ours.

We are

currently involved in competitive binding experiments to definitively prove that
IL-1 induces the expression of IL-4 receptors.
The finding that IL-1 and IL-4 are synergistic on HT-2 cells is most
intriguing.

The HT-2 cell line is unlike most other cloned murine T helper cell

lines in that it is strictly dependent on TCGF and does not require antigen for its
growth156.

Furthermore, this cell line constitutively expresses a very high

number (>10,000) of high affinity receptors (R. Robb personal communication).
The ability of the cell line to respond to IL-1 and IL-4 argues that HT-2 cells
maintain at least some degree of control over lymphokine receptor expression
and that observations deduced from this cell may also be relevant to other cell
lines.
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The findings that DIO ceils could be pretreated with IL-1 and then be
subsequently stimulated to maximal proliferation with only 3D3 suggests that
“resting” DIO under the currently employed cell culturing conditions expresses
IL-1 receptors.

Previous experiments have demonstrated that “resting” DIO

expresses about 1,000 high affinity IL-2 receptors (R.

Robb and JBH,

unpublished observations). Additionally, it appears that “resting” DIO does not
express significant numbers of IL-4 receptors; however, stimulation with IL-1 in
the presence of IL-1 receptor most probably induces IL-4 receptor expression.
Thus it appears that DIO is unlike resting T cells in that it expresses both IL-1
and IL-2 receptors.

These findings make the DIO cell line ideal for studying

lymphokines given the presence of lymphokine receptors on its plasma
membrane.
In summary, it appears that there are at least two possible explanations
of why DIO fails to proliferate in response to 3D3. The first explanation is that in
addition to IL-4 DIO produces an inhibitor of IL-2 and possibly IL-4.

Another

reason for the failure of DIO to grow in response to apparently high levels of IL4 may reside in the observation that DIO does not express significant numbers
of IL-4 receptors. The relative contribution each plays has yet to be definitively
determined; however, the initial evidence suggests that the latter may be more
important.
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